Stockscreener 앱 받기
5.52
3.66%
-0.21
시간 외 거래:
5.52
전일 마감가:
$5.73
열려 있는:
$5.73
하루 거래량:
277.19K
Relative Volume:
0.62
시가총액:
$51.98M
수익:
-
순이익/손실:
$-81.17M
주가수익비율:
-0.5447
EPS:
-10.1344
순현금흐름:
$-82.84M
1주 성능:
-13.88%
1개월 성능:
-85.51%
6개월 성능:
-60.00%
1년 성능:
-89.63%
1일 변동 폭
$5.4201
$5.7899
1주일 범위
$5.4201
$6.59
52주 변동 폭
$5.4201
$56.04
Korro Bio Inc Stock (KRRO) Company Profile
명칭
Korro Bio Inc
전화
617-468-1999
주소
60 FIRST STREET, CAMBRIDGE
KRRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
5.52 | 53.96M | 0 | -81.17M | -82.84M | -10.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-11-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2025-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-11-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-13 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2025-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-16 | 개시 | Chardan Capital Markets | Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Raymond James | Strong Buy |
| 2024-08-14 | 개시 | William Blair | Outperform |
| 2024-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2024-02-27 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-04 | 개시 | H.C. Wainwright | Buy |
| 2023-11-29 | 개시 | RBC Capital Mkts | Outperform |
| 2023-11-10 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-01-27 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-22 | 개시 | B. Riley Securities | Buy |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-10-28 | 개시 | Cowen | Outperform |
| 2019-10-28 | 개시 | Goldman | Buy |
| 2019-10-28 | 개시 | JP Morgan | Overweight |
모두보기
Korro Bio Inc 주식(KRRO)의 최신 뉴스
Korro Bio, Inc. Experiences Revision in Stock Evaluation Amid Mixed Financial Performance - Markets Mojo
Korro Bio’s RNA Editing Ambitions Take A Hit After Trial Blowup - Finimize
Korro Bio downgraded to Perform from Outperform at Oppenheimer - MSN
What high frequency data says about Korro Bio Inc.Portfolio Profit Report & Daily Oversold Bounce Ideas - newser.com
Will Korro Bio Inc. stock benefit from automationBear Alert & Technical Analysis for Trade Confirmation - newser.com
What indicators show strength in Korro Bio Inc.Portfolio Value Report & Consistent Income Trade Recommendations - newser.com
Will Korro Bio Inc. stock deliver strong dividend growthPortfolio Performance Summary & Growth Focused Investment Plans - newser.com
What makes Korro Bio Inc. stock attractive to growth fundsJuly 2025 News Drivers & Weekly High Return Stock Forecasts - newser.com
What is the fair value of Korro Bio Inc. stock nowJuly 2025 Earnings & Reliable Volume Spike Alerts - newser.com
Korro Bio, Inc.Common Stock (NQ: KRRO - FinancialContent
Korro Bio (KRRO) Price Target Decreased by 30.76% to 66.30 - MSN
Korro Bio stock fell after missing expectations in early stage KRRO-110 trial - MSN
How to track smart money flows in Korro Bio Inc.July 2025 Catalysts & Community Consensus Stock Picks - newser.com
Why Korro Bio Inc. stock is favored by pension fundsWeekly Trend Recap & Community Trade Idea Sharing Platform - newser.com
Can Korro Bio Inc. stock hit record highs againWeekly Trade Summary & Real-Time Sentiment Analysis - newser.com
Published on: 2025-11-16 03:17:25 - newser.com
William Blair Downgrades Korro Bio (KRRO) - MSN
Will Korro Bio Inc. stock attract more institutional investorsPortfolio Performance Summary & Fast Moving Trade Plans - newser.com
Korro Bio downgraded to Neutral from Buy at Chardan - MSN
Korro Bio downgraded to Neutral from Overweight at Cantor Fitzgerald - MSN
Korro Bio downgraded to Market Perform from Strong Buy at Raymond James - MSN
Korro Bio (KRRO): Assessing Valuation After Clinical Setbacks, Layoffs, and Strategic Pivot - Yahoo Finance
Why Korro Bio (KRRO) Is Down 80.0% After Restructuring, Clinical Trial Miss, and CMO Resignation - simplywall.st
Korro Bio Inc. (KRRO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Reversal indicators forming on Korro Bio Inc. stockBuy Signal & Accurate Entry and Exit Point Alerts - newser.com
Korro Bio Stock Crashes Over 75% After-Hours On Drug Failure, Downgrades And Layoffs — Yet Retail Flags ‘Buy-The-Fear’ Setup - Stocktwits
KRRO Downgraded to Hold by Jones Trading Amidst Industry Adjustm - GuruFocus
Korro Bio’s Strategic Shift Amidst Clinical Setbacks and Financial Stability Justifies Hold Rating - TipRanks
HC Wainwright & Co. Downgrades Korro Bio (KRRO) - MSN
Healthcare Stocks Tumble As Companies Shift Strategies - Finimize
Cantor Fitzgerald downgrades Korro Bio stock to Neutral after lead asset failure - Investing.com Canada
Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editing - MSN
JonesResearch downgrades Korro Bio on KRRO-110 failure - TipRanks
Backtrack to GalNAc: Korro AATD strategy Rewrite post-fizzle - BioWorld MedTech
Biotech Crashes To Record Low On RNA-Editing Failure - Investor's Business Daily
More cuts at Korro as lead drug disappoints, Novo pauses collab - FirstWord Pharma
KRRO’s Sudden Decline: Time to Re-evaluate? - StocksToTrade
Korro Bio Early Trial Results Fall Short; Stock Hits New Low - inkl
KRRO Faces Major Downgrade as RBC Capital Lowers Price Target | - GuruFocus
Korro Bio reports Q3 EPS ($1.92), consensus ($2.68) - MSN
What analysts say about Korro Bio Inc stockHealthcare Stock Analysis & What the Pros Are Saying About This Stock - earlytimes.in
Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates - MSN
Korro Bio Inc (KRRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.76%
2.16%
자본화:
|
볼륨(24시간):